Active Biotech AB (publ) announced the successful completion of the dose escalation of tasquinimod in combination with the orally administered antimyeloma agents ixazomib, lenalidomide, and dexamethasone (IRd) in patients with relapsed or refractory multiple myeloma. 6 patients have been treated with increasing doses of tasquimod in combination with IRd and the combination was well tolerated with no protocol-defined dose limiting toxicities. The optimal dose and the treatment schedule of tasquinimod, when used in combination with IRd in patients with multiple myeloma was established at 1 mg per day after a one-week run in of 0.5 mg daily.

This is similar to the treatment schedule established for tasquinimod used in monotherapy in patients with multiple myelomas. At present, two patients are ongoing in the combination part of the study.